[의학신문·일간보사=김영주 기자]Yuhan Corporation (CEO Wook-Je Cho) will present the preclinical efficacy and toxicity test results of the immuno-oncology double antibody (YH32367/ABL105), which is being developed as a new anticancer treatment, at an international conference.
The results of this study will be presented at the poster session of the annual symposium of the European Society for Oncology (ESMO) on September 16 (Europe local time), and the related abstract was released on the conference website on September 13 (Europe local time). .
YH32367 is a drug jointly researched by Yuhan Corporation and ABL Bio (CEO Lee Sang-hoon). It is an anticancer drug that specifically binds to tumor cells and increases the anticancer activity of immune cells through stimulation of 4-1BB, a T-immune cell activating receptor. all.
It is a dual antibody that is being developed for the treatment of patients who are resistant to existing anticancer drugs by increasing tumor-specific immune activity and inhibiting the growth of tumor cells at the same time. Representative indications are a number of solid cancers such as breast cancer, gastric cancer, and lung cancer.
As YH32367 has a similar mechanism, Yuhan expects that it will stand out not only in Korea but also in the global anticancer drug market if these features are proven in clinical trials.
According to the published abstract, YH32367 increased the secretion of apoptotic cytokines such as interferon gamma and induced tumor cell death in human T-immune cells. It showed excellent anticancer efficacy.
In addition, YH32367 eliminated the side effect of hepatotoxicity, which is a disadvantage of competing drugs, and its safety was confirmed in the preclinical toxicity test that is currently in the final stage.
Yuhan Corporation is developing YH32367 with the goal of starting clinical trials in 2022.
.
